M
Medrio
Based in San Francisco, Medrio has been building a true eClinical / EDC Software as a Service (SaaS) solution for clinical trials since 2005.
About Medrio
Medrio is a technology company specializing in providing software solutions for clinical trials. Founded in 2005, the company operates in the healthcare and life sciences market, serving clients such as pharmaceutical companies, biotech firms, and contract research organizations (CROs). Medrio's primary offering is its cloud-based platform designed to streamline various aspects of clinical trials, from protocol design to casebook submission.
The company's solutions include Randomization and Trial Supply Management (RTSM), which helps clients effectively randomize, manage, and control their trial supplies while minimizing risks. Medrio's platform also features advanced tools for configuring allocation rules, automating shipment approvals, and receiving issue notifications, thereby enhancing the efficiency of the supply chain process.
Medrio's business model is based on a Software-as-a-Service (SaaS) approach, where clients subscribe to use its platform. This model ensures a recurring revenue stream for the company. Medrio makes money through subscription fees, which vary based on the features and scale of the services utilized by the clients.
The company prides itself on its user-friendly interface, which allows researchers to focus on the science rather than the technology. Medrio also emphasizes a culture of inclusion, diversity, and a joyful work environment, which it believes contributes to its innovative and effective solutions.
In summary, Medrio is a key player in the clinical trial software market, offering robust and user-friendly solutions that help streamline and manage the complexities of clinical research. Its SaaS business model ensures steady revenue, and its commitment to a positive work culture and technological innovation positions it well for continued growth.
Source: Dealroom company dataKnowledge graph
More headlines
Funding history
Company financing events and reported valuations.
| Deal type | Date | Amount | Valuation | Investors | Source |
|---|---|---|---|---|---|
| LATE VC✓Equity / VC | May 2017 | $30M | $120M | Questa Capital Management | — |
| SEEDEquity / VC | Feb 2014 | — | — | Stanford Angels and Entrepreneurs | — |
Growth signals
Latest recorded traffic for Medrio is 180K monthly website visits, up 20% over the last three months. Medrio's team grew 4% over the past year.
Similar companies
Company identity and context are open; selected comparison metrics preview what is available on the platform.
Investments and acquisitions
Recent portfolio relationships for companies that also act as investors or acquirers.
Investors
From Dealroom's funding and investor records, grouped by the round each investor first entered.
Seed1 investor entered at this stage
Stanford Angels and Entrepreneurs
Series A5 investors entered at this stage
TSVC
Safa Rashtchy
Questa Capital ManagementUlu Ventures
- T+Think +
Other known investors2 additional known investors
Montage Capital
SeedFolio
Source: Dealroom Talent Intelligence.
Global footprint
team presence
Market sentiment
An AI-synthesised read of the highest-engagement posts about Medrio on X, ranked by likes and reposts, corporate channels excluded.
Reading the room on X — pulling top posts and synthesizing themes…
Source: X recent search ranked by engagement (likes + retweets) · Synthesis by Claude · Cached for 1 hour
See Medrio’s full profile on Dealroom
Request a free trial to see the complete deal history, financials, people graph and growth signals.
Takes under a minute. Already use Dealroom? Log in.






